can produce either a chronic or latent infection and can be reactivated by various internal or external triggers. Herpes simplex virus-1, HSV-2, and VZV induce a lifelong latent state within nervous tissue, whereas EBV, CMV, HHV-6, and HHV-7 are latent within the lymphocyte subpopulation.
Typically, primary infections with HSV-1, HSV-2, and VZV involve the skin. Cytomegalovirus in children with malignancy. Pregnant and postpartum women also have an increased risk. An overall mortality rate of 40 percent has been reported for varicella pneumonia. Bacterial superinfection is common following VZV pneumonia, and long-term sequelae in terms of lung dysfunction are well defined. Treatment with intravenous acyclovir has been employed with apparent success; however, there is little information on the benefit of oral acyclovir in this clinical situation. One noncontrolled study has demonstrated benefit for prophylactic oral acyclovir during the second and third weeks of varicella exposure. Whether the use of the soon-to-be-licensed live-attenuated varicella vaccine will reduce the incidence of VZV pneumonia is still to be determined. 2 Involvement of the lower respiratory tract by HSV was first reported in 1970 by Nash Cytomegalovirus has been recovered from the lower respiratory tract in ventilated patients, but the role of this virus in causing pneumonia or respiratory failure is difficult to document.6 Clinically inapparent infection is probably most common; fever and leukocytosis are rare. No treatment studies are available for CMV pulmonary involvement except following bone marrow transplantation.7
These papers suggest that many important questions still need to be addressed concerning lower respiratory tract infections due to herpesviruses. What is the pathogenesis of HSV infection in the lower respiratory tract? How can one differentiate colonization rates or asymptomatic virus shedding from infection and disease? What is the risk of nosocomial infection and potential spread to health-care personnel? Who should receive specific antiviral therapy or prophylaxis?
From these reviews, we have learned that the pathogenesis of HSV pulmonary involvement is not completely understood. Hematogenous spread could occur but is unlikely to, since visceral involvement is rarely found in autopsies from patients with HSV lung pathology. Contiguous spread or aspiration of HSV is probably more likely.8 The importance of local trauma and/or immunosuppression for reactivation of HSV has been discussed and supported by animal studies. Quantitative lower respiratory tract viral cultures might differentiate "colonization" from infection and should be studied. Surveillance viral cultures in ventilator patients could be used to document possible transmission of virus to health-care personnel or to other patients. This would solidify our knowledge of the potential for nosocomial spread with these herpesviruses. Although the published studies of acyclovir treatment have demonstrated the antiviral effect in lower respiratory tract herpesvirus infections, clinical benefit has been difficult to prove. Only after answering these questions will we be able to address whether targeted treatment would be beneficial in specific subgroups. The papers in this supplement provide a point of departure for future research.
